US Patent

US10478494 — FGFR/PD-1 combination therapy for the treatment of cancer

Method of Use · Assigned to Astex Therapeutics Ltd · Expires 2036-08-13 · 10y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of treating cancer in patients with specific FGFR variants by administering an FGFR inhibitor and an antibody that blocks the PD-1/PD-L1 interaction.

USPTO Abstract

Provided herein are combination therapies for the treatment of cancer. In particular, the disclosed methods are directed to treatment of cancer in a patient comprising administering an antibody that blocks the interaction between PD-1 and PD-L1 and an FGFR inhibitor, wherein the antibody that blocks the interaction between PD-1 and PD-L1 and the FGFR inhibitor are administered if one or more FGFR variants are present in a biological sample from the patient.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3902 — Balversa
U-3902 — Balversa
U-3902 — Balversa

Patent Metadata

Patent number
US10478494
Jurisdiction
US
Classification
Method of Use
Expires
2036-08-13
Drug substance claim
No
Drug product claim
No
Assignee
Astex Therapeutics Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.